Experts Propose 10-Year Trial to Test GLP-1 Drugs for Cancer Prevention
A panel of 21 obesity and cancer experts proposed a 5,000-participant, decade-long trial to test whether semaglutide and tirzepatide can prevent obesity-related cancers.
#Semaglutide
132 stories
Semaglutide is the active ingredient in Ozempic and Wegovy. Novo Nordisk holds the patent in most markets through 2031, but the Indian patent expired in March 2026 and a wave of generics from Biocon, Dr. Reddy's, and others followed within weeks.
The cardiovascular and renal evidence has expanded fastest. SELECT showed a 20% reduction in MACE for non-diabetic adults with obesity. The REMODEL trial (presented at the World Congress of Nephrology 2026) showed direct kidney protection independent of weight loss. Cell Metabolism work from Sinai Health pinned MASH reversal to liver sinusoidal endothelial cells, not weight loss or appetite. JAMA published a 90,000-patient HFpEF analysis showing a 42% reduction in heart-failure hospitalization or all-cause mortality.
The compounding story keeps moving in parallel. The FDA proposed excluding semaglutide from the 503B bulks list on April 30, 2026, with public comment open through June 29. Tirzepatide and liraglutide were folded into the same proposal.
On September 7, 2026, Novo reported first Phase 3 results in children under 12: the STEP Young trial in 165 children aged 6 to under 12 years with obesity showed 40.4% below the obesity threshold at week 68 on semaglutide (max 1.7 mg or 2.4 mg by baseline weight) plus lifestyle modification, versus 0% on placebo; safety matched adult and adolescent experience, with no signal for growth or pubertal development. Detailed results are due at ObesityWeek 2026 in Washington DC (November 14-17). A supplemental filing to extend the U.S. Wegovy label below the current 12-and-older indication has not been announced.
FDA Approves Higher 2 mg Dose of Ozempic for Type 2 Diabetes
The FDA approved a new 2 mg dose of Ozempic (semaglutide) injection, providing an additional option for patients needing more intensive glycemic management.
Semaglutide Linked to 42% Drop in Psychiatric Hospital Visits
Large-scale study from University of Eastern Finland and Karolinska Institutet found GLP-1 medications associated with 42% drop in psychiatric hospital visits, 44% lower depression risk, and 47% reduced substance use disorders.
Compounded GLP-1 Prescriptions Keep Rising Despite FDA Crackdown
Healthcare Brew reports that despite the FDA sending thousands of warning letters since September 2025, compounded semaglutide and tirzepatide prescriptions have increased since the semaglutide shortage ended in February 2025. About 80% of compounded GLP-1 prescriptions now include supplemental ingredients like B vitamins to avoid being classified as exact copies of FDA-approved drugs.
Cleveland Clinic Study: Most Patients Avoid Dramatic Weight Regain After Stopping GLP-1 Drugs
A Cleveland Clinic analysis of 7,938 adults who discontinued semaglutide or tirzepatide found that real-world outcomes are better than clinical trials suggested. Obesity patients regained just 0.5% of body weight on average after one year, and 45% either maintained or continued losing weight by restarting treatment, switching medications, or adopting lifestyle changes.
GLP-1 Lawsuits Surpass 3,500 Pending Cases as Vision Loss Claims Surge
Over 3,546 lawsuits are now consolidated in two federal MDLs — one for gastroparesis and one for NAION vision loss. On March 3, a federal judge appointed lead counsel for the NAION MDL. Studies show semaglutide users face a fourfold increase in NAION risk, with vision loss claims now generating more legal attention than earlier gastroparesis cases.